Elizabeth J. Ackermann

4.2k total citations · 1 hit paper
35 papers, 2.4k citations indexed

About

Elizabeth J. Ackermann is a scholar working on Molecular Biology, Cell Biology and Nephrology. According to data from OpenAlex, Elizabeth J. Ackermann has authored 35 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 10 papers in Cell Biology and 4 papers in Nephrology. Recurrent topics in Elizabeth J. Ackermann's work include Amyloidosis: Diagnosis, Treatment, Outcomes (18 papers), Protein Kinase Regulation and GTPase Signaling (9 papers) and Cellular transport and secretion (7 papers). Elizabeth J. Ackermann is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (18 papers), Protein Kinase Regulation and GTPase Signaling (9 papers) and Cellular transport and secretion (7 papers). Elizabeth J. Ackermann collaborates with scholars based in United States, United Kingdom and Brazil. Elizabeth J. Ackermann's co-authors include Edward A. Dennis, Kilian W. Conde‐Frieboes, C. Frank Bennett, Dario C. Altieri, E.S. Kempner, Fengzhi Li, Annette L. Rothermel, Simona Tognin, Pier Carlo Marchisio and Antonello Villa and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of the American College of Cardiology.

In The Last Decade

Elizabeth J. Ackermann

35 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

1999 526 citations Elizabeth J. Ackermann, C. Frank Bennett et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth J. Ackermann United States	18	1.9k	416	410	270	250	35	2.4k
Dongmei Zuo Canada	27	1.6k 0.8×	385 0.9×	311 0.8×	214 0.8×	197 0.8×	54	2.2k
Masayoshi Yada Japan	17	2.1k 1.1×	863 2.1×	446 1.1×	287 1.1×	230 0.9×	45	3.1k
Laura Moro Italy	23	1.1k 0.6×	436 1.0×	408 1.0×	190 0.7×	137 0.5×	55	2.2k
Anna Maria Billi Italy	32	2.0k 1.0×	276 0.7×	521 1.3×	203 0.8×	174 0.7×	93	2.6k
Tai-An Lin United States	17	2.2k 1.1×	285 0.7×	371 0.9×	264 1.0×	218 0.9×	20	2.9k
Christopher Belham United Kingdom	15	2.3k 1.2×	287 0.7×	629 1.5×	309 1.1×	359 1.4×	16	3.0k
Qingyuan Ge United States	17	1.9k 1.0×	360 0.9×	260 0.6×	168 0.6×	294 1.2×	19	2.5k
Anutosh Chakraborty United States	23	1.3k 0.7×	619 1.5×	529 1.3×	313 1.2×	244 1.0×	36	2.2k
Jingxiang Huang Singapore	15	1.9k 1.0×	390 0.9×	280 0.7×	264 1.0×	733 2.9×	22	2.8k
Stephen R. James United Kingdom	13	2.6k 1.4×	282 0.7×	502 1.2×	324 1.2×	239 1.0×	19	3.2k

Countries citing papers authored by Elizabeth J. Ackermann

Since Specialization

Citations

This map shows the geographic impact of Elizabeth J. Ackermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth J. Ackermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth J. Ackermann more than expected).

Fields of papers citing papers by Elizabeth J. Ackermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth J. Ackermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth J. Ackermann. The network helps show where Elizabeth J. Ackermann may publish in the future.

Co-authorship network of co-authors of Elizabeth J. Ackermann

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth J. Ackermann. A scholar is included among the top collaborators of Elizabeth J. Ackermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth J. Ackermann. Elizabeth J. Ackermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dyck, P. James B., P. James B. Dyck, Teresa Coelho, et al.. (2020). Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle & Nerve. 62(4). 509–515. 15 indexed citations

Dyck, P. James B., P. James B. Dyck, John C. Kincaid, et al.. (2020). mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis. Muscle & Nerve. 62(4). 502–508. 8 indexed citations

Yu, Rosie Z., Elizabeth J. Ackermann, Richard S. Geary, et al.. (2020). Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis. Nucleic Acid Therapeutics. 30(3). 153–163. 25 indexed citations

Yarlas, Aaron, Morie A. Gertz, Noel R. Dasgupta, et al.. (2019). Burden of hereditary transthyretin amyloidosis on quality of life. Muscle & Nerve. 60(2). 169–175. 36 indexed citations

Waddington‐Cruz, Márcia, Elizabeth J. Ackermann, Michael Polydefkis, et al.. (2018). Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid. 25(3). 180–188. 22 indexed citations

Maurer, Mathew S., Stephen B. Heitner, Brian Drachman, et al.. (2018). INOTERSEN IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY AND CARDIOMYOPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTR. Journal of the American College of Cardiology. 71(11). A658–A658. 5 indexed citations

Pinto, Marcus Vinícius, P. James B. Dyck, Bryan M. McCauley, et al.. (2018). Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy. Journal of the Neurological Sciences. 394. 78–83. 8 indexed citations

Benson, Merrill D., Elizabeth J. Ackermann, & Brett P. Monia. (2017). Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTR_Rx). Amyloid. 24(sup1). 134–135. 9 indexed citations

Sauer, Vanessa, Jacqueline Stella, Lutz Fleischhauer, et al.. (2016). Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells. PLoS ONE. 11(9). e0161455–e0161455. 19 indexed citations

10.

Ackermann, Elizabeth J., Shuling Guo, Merrill D. Benson, et al.. (2016). Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid. 23(3). 148–157. 114 indexed citations

11.

Benson, Merrill D., John C. Kincaid, Elizabeth J. Ackermann, & Brett P. Monia. (2015). A Phase 3 Study to Evaluate ISIS-TTR _Rx in Patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Study Design and Baseline Demographics (S50.006). Neurology. 84(14_supplement). 3 indexed citations

12.

Barnes, Helen, Elizabeth J. Ackermann, & Peter van der Geer. (2003). v-Src induces Shc binding to tyrosine 63 in the cytoplasmic domain of the LDL receptor-related protein 1. Oncogene. 22(23). 3589–3597. 56 indexed citations

13.

Ackermann, Elizabeth J., et al.. (1999). The Role of Antiapoptotic Bcl-2 Family Members in Endothelial Apoptosis Elucidated with Antisense Oligonucleotides. Journal of Biological Chemistry. 274(16). 11245–11252. 95 indexed citations

14.

Ackermann, Elizabeth J., et al.. (1998). Identification of Pairwise Interactions in the α-Neurotoxin-Nicotinic Acetylcholine Receptor Complex through Double Mutant Cycles. Journal of Biological Chemistry. 273(18). 10958–10964. 62 indexed citations

15.

Marchot, P., Joan R. Kanter, Shelley Camp, et al.. (1997). Expression and Activity of Mutants of Fasciculin, a Peptidic Acetylcholinesterase Inhibitor from Mamba Venom. Journal of Biological Chemistry. 272(6). 3502–3510. 34 indexed citations

16.

Ackermann, Elizabeth J. & Palmer Taylor. (1997). Nonidentity of the α-Neurotoxin Binding Sites on the Nicotinic Acetylcholine Receptor Revealed by Modification in α-Neurotoxin and Receptor Structures. Biochemistry. 36(42). 12836–12844. 39 indexed citations

17.

Ackermann, Elizabeth J. & Edward A. Dennis. (1995). Mammalian calcium-independent phospholipase A2. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1259(2). 125–136. 109 indexed citations

18.

Balsinde, Jesús, Ismael D. Bianco, Elizabeth J. Ackermann, Kilian W. Conde‐Frieboes, & Edward A. Dennis. (1995). Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages.. Proceedings of the National Academy of Sciences. 92(18). 8527–8531. 245 indexed citations

19.

Ackermann, Elizabeth J., Kilian W. Conde‐Frieboes, & Edward A. Dennis. (1995). Inhibition of Macrophage Ca2+-independent Phospholipase A2 by Bromoenol Lactone and Trifluoromethyl Ketones. Journal of Biological Chemistry. 270(1). 445–450. 362 indexed citations

20.

Ackermann, Elizabeth J., E.S. Kempner, & Edward A. Dennis. (1994). Ca(2+)-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization.. Journal of Biological Chemistry. 269(12). 9227–9233. 224 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact